Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results
November 18, 2021 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call...
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
November 17, 2021 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
October 26, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
October 14, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing...
Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
September 16, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to...